Welcome to our dedicated page for Pluri SEC filings (Ticker: PLUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pluri Inc. (PLUR) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. Pluri is a Nevada-incorporated biotechnology company that reports operating from Haifa, Israel and lists its common shares on Nasdaq and the Tel Aviv Stock Exchange. Through its filings, investors can review how Pluri describes its business, governance, capital structure and material events related to its cell-based platform and collaborative ventures.
Key documents for Pluri include current reports on Form 8-K, which the company uses to announce material agreements, board and leadership changes, equity awards and private placements. For example, recent 8-K filings describe a Securities Purchase Agreement with an entity beneficially owned by a director for a private placement of common shares and warrants, equity grants to executives and directors, and changes in board composition and committee membership following shareholder meetings. These filings also document matters such as Nasdaq listing rule compliance and shareholder voting results.
Investors analyzing PLUR can use annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) to understand the company’s description of its 3D cell expansion platform, its operations in regenerative medicine, foodtech, agtech, aesthetics and CDMO services, and its network of subsidiaries and collaborations. Proxy statements and related materials provide additional detail on board structure, compensation plans and shareholder proposals.
On Stock Titan, Pluri’s SEC filings are complemented by AI-powered summaries designed to highlight the main points of lengthy documents, such as complex agreements or governance disclosures. Users can quickly see what each filing covers, from private placement terms and warrant structures to board appointments and committee roles, and then drill down into the full text for deeper analysis. The filings page also helps track equity issuances, compensation-related grants and other regulatory information that may be relevant to understanding PLUR as a publicly traded biotechnology company.
Pluri Inc. reported that insider-affiliated investor Chutzpah Holdings LP, which is beneficially owned by director and 10% owner Alexandre Weinstein, agreed to a private placement under a March 24, 2026 Securities Purchase Agreement. The deal covers 625,000 common shares and common warrants to purchase 625,000 common shares at a combined price of $4.00 per share and accompanying warrant.
The agreement closed in two tranches: on March 31, 2026 and April 21, 2026, CHLP acquired 312,500 common shares and common warrants to purchase 312,500 common shares at each closing, providing total gross proceeds of $2,500,000 to Pluri. The common warrants are exercisable immediately at $4.25 per share and expire 18 months after issuance, with a hard 35% beneficial ownership cap. The filing also details Weinstein’s indirect holdings through CHLP and related entities, as well as his vested and scheduled-to-vest restricted stock units.
Pluri Inc. investor group updates its ownership disclosure. Chutzpah Holdings Limited, Chutzpah Holdings LP (CHLP), Plantae Bioscience and Alexandre Weinstein now report aggregate beneficial ownership of 3,794,897 Pluri common shares, representing approximately 34.98% of the company’s outstanding stock.
CHL beneficially owns 2,018,014 shares, including 1,933,415 common shares and warrants for 84,599 shares. CHLP beneficially owns 1,317,897 shares, combining 1,250,000 common shares with 110,000 warrant shares counted under a 35% Beneficial Ownership Limitation. Plantae holds 452,702 shares. Mr. Weinstein’s total includes these indirect holdings plus 6,284 shares and RSUs held directly.
Pluri Inc. is asking shareholders to vote at its June 15, 2026 annual meeting in Haifa, Israel on two main items: electing five directors and ratifying Kesselman & Kesselman (a PwC member firm) as independent auditors for the year ending June 30, 2026.
The record date is April 23, 2026, when 10,774,666 common shares were outstanding, each with one vote. A quorum requires at least 33⅓% of voting power present. The proposed board slate includes Chairman Alexandre Weinstein and CEO Yaky Yanay.
The proxy details committee structures, director independence, and executive pay, including CEO total compensation of $1.50 million for fiscal 2025 and equity-heavy incentives. It also discloses a related-party Kokomodo acquisition, where a Pluri subsidiary bought approximately 79% of Kokomodo Ltd. from entities controlled by Chairman Weinstein for $4.5 million, paid in 976,139 Pluri shares, plus assignment of a $0.5 million convertible loan.
Pluri Inc. entered into a securities purchase agreement for a private placement of 625,000 common shares and warrants to purchase up to 625,000 common shares, at a combined price of $4.00 per share and warrant, expected to generate approximately $2.5 million in gross proceeds.
The investor is Chutzpah Holdings LP, a limited partnership beneficially owned by existing shareholder and director Alexandre Weinstein. The warrants are immediately exercisable at $4.25 per share for eighteen months and include a 35% beneficial ownership limitation. Pluri plans to use the funds for working capital and general corporate purposes, with closing expected around the end of April 2026, subject to customary conditions. The securities are being issued in an unregistered offering relying on exemptions under Section 4(a)(2) and/or Regulation S and cannot be sold in the United States without registration or a valid exemption.
Pluri Inc. reports it has regained compliance with Nasdaq’s market value listing standard. Nasdaq notified the company that, for 10 consecutive business days from February 13, 2026 to February 26, 2026, the market value of Pluri’s listed securities was at least $35 million, meeting Listing Rule 5550(b)(2).
Because this requirement is now satisfied, Nasdaq has closed the deficiency matter and Pluri’s shares remain in good standing on The Nasdaq Capital Market. Earlier, Nasdaq had warned Pluri that it did not meet the required market value or the alternative stockholders’ equity or net income standards.
Pluri Inc. reported wider losses and growing liquidity pressure for the six months ended December 31, 2025. Revenue was broadly flat at $514,000 versus $511,000 a year earlier, mainly from CDMO services and AgTech proof-of-concept collaborations.
Net loss rose to $13.0 million from $9.1 million, driven by higher research and development spending of $7.8 million and general and administrative expenses of $5.3 million. Cash, cash equivalents, short-term deposits, restricted cash and restricted bank deposits totaled $13.6 million as of December 31, 2025, against a working capital deficit of $18.5 million and an accumulated deficit of $455.4 million.
The balance sheet is constrained by an EIB loan with principal of $23.5 million and accrued interest of $4.3 million due June 1, 2026, and management acknowledges “substantial doubt” about the company’s ability to continue as a going concern, estimating less than six months of funding from the February 2026 reporting date. Pluri raised $2.5 million in a December 2025 private placement and $300,000 via a SAFE at subsidiary Kokomodo, and received a Nasdaq notice on January 20, 2026 for not meeting the $35 million market value of listed securities requirement.
Pluri Inc. reported that it received a notice from Nasdaq on January 20, 2026 stating that the company no longer meets Nasdaq’s continued listing standards for The Nasdaq Capital Market. Pluri’s market value of listed securities has fallen below the required $35 million, and it also does not meet the alternative standards of at least $2.5 million in stockholders’ equity or $500,000 in net income over the specified periods.
The company’s common shares will continue to trade on Nasdaq under the symbol PLUR during an initial 180‑day compliance period ending on July 20, 2026. Pluri can regain compliance if its market value of listed securities is at or above $35 million for at least 10 consecutive business days, and it is evaluating options to achieve this. If it fails to regain compliance, its shares would be subject to delisting, though the company would have the right to appeal to a Nasdaq Hearings Panel.
Pluri Inc. entered into a securities purchase agreement with Chutzpah Holdings LP, a fund beneficially owned by director Alexandre Weinstein, for a private placement of 625,000 common shares and warrants to purchase up to 625,000 additional shares. The units are priced at $4.00 per share plus warrant, for expected gross proceeds of approximately $2.5 million, with warrants exercisable immediately at $4.25 per share until June 30, 2026 and subject to a 35% beneficial ownership cap. The closing is expected on or about December 15, 2025, subject to customary conditions, and proceeds are earmarked for working capital and general corporate purposes.
The board granted 10,248 restricted stock units to the CEO and CFO and 2,885 RSUs to directors in lieu of cash compensation, vesting monthly over three months to support cost management and align incentives. Effective December 4, 2025, Alexandre Weinstein was appointed Chairman of the Board and Zami Aberman was appointed Vice Chairman, with Aberman’s consultancy agreement ending January 4, 2026.
Pluri Inc. reported that Chief Executive Officer and director Yaky Yanay received a grant of 6,588 restricted stock units of common stock on December 4, 2025, at a price of $0 per share under the company's 2019 Equity Compensation Plan.
The RSUs vest in equal installments on a monthly basis over three months following the grant date. After this award, Yanay beneficially owns 497,758 shares of common stock directly and 836 shares indirectly through Yaacov Yanay Management Ltd.